<DOC>
	<DOCNO>NCT01532973</DOCNO>
	<brief_summary>The purpose study assess safety , pharmacokinetics ( PK ) pharmacodynamics elbasvir ( MK-8742 ) Hepatitis C Virus ( HCV ) -infected participant . There 3 part study ; Part I enroll genotype ( GT ) 1 HCV-infected participant , Part II enroll GT3 HCV-infected participant , Part III enroll GT1a HCV-infected participant . All part may run concurrently , Parts II III may stagger . Hypothesis ( Part I ) : At once-daily dose sufficiently safe well tolerate HCV-infected participant , elbasvir administer 5 consecutive day superior antiviral activity GT1 HCV-infected participant compare placebo , measure change baseline plasma HCV ribonucleic acid ( RNA ; log 10 copies/mL ) Day 5 , 24-hour postdose timepoint . ( true mean viral RNA reduction least 3 log10 anticipate ) . Hypothesis ( Part II ) : At dose sufficiently safe GT3 HCV-infected participant , mean maximum reduction HCV viral load great follow multiple dose oral administration elbasvir compare placebo . Hypothesis ( Part III ) : At once-daily dose sufficiently safe well tolerate HCV-infected participant , elbasvir administer 5 consecutive day superior antiviral activity GT1a HCV-infected participant compare placebo , measure change baseline plasma HCV RNA ( log 10 copies/mL ) Day 5 , 24-hour postdose timepoint . ( true mean viral RNA reduction least 3 log10 anticipate ) .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics Elbasvir ( MK-8742 ) Hepatitis C Infected Males ( MK-8742-002 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Viral , Human</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18 ≤ 37 kg/m^2 Clinical diagnosis chronic HCV infection define positive serology HCV least 6 month detectable HCV RNA peripheral blood ≥105 IU/mL screen Participant must infect HCV GT1a , GT1b , GT 3 Coinfection GT1 GT3 Estimated creatinine clearance ≤70 mL/min base CockcroftGault equation History stroke , chronic seizure , major neurological disorder History clinically significant endocrine , gastrointestinal ( except HCV infection ) , cardiovascular , hematological , immunological , renal , respiratory , genitourinary abnormality diseases History neoplastic disease Positive Hepatitis B surface antigen prestudy ( screen ) visit Has major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior prestudy ( screen ) visit . Previous treatment ( ) nonstructural protein 5A ( NS5A ) inhibitor &lt; 4 week since administration experimental protease inhibitor Previous exposure interferonalpha and/or ribavirin within 3 month prior first dose elbasvir study Clinical laboratory evidence advance decompensated liver disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>